Novel therapies for relapsed and refractory neuroblastoma

Research output: Contribution to journalReview articlepeer-review

41 Scopus citations


While recent increases in our understanding of the biology of neuroblastoma have allowed for more precise risk stratification and improved outcomes for many patients, children with high-risk neuroblastoma continue to suffer from frequent disease relapse, and despite recent advances in our understanding of neuroblastoma pathogenesis, the outcomes for children with relapsed neuroblastoma remain poor. These children with relapsed neuroblastoma, therefore, continue to need novel treatment strategies based on a better understanding of neuroblastoma biology to improve outcomes. The discovery of new tumor targets and the development of novel antibody-and cell-mediated immunotherapy agents have led to a large number of clinical trials for children with relapsed neuroblastoma, and additional clinical trials using molecular and genetic tumor profiling to target tumor-specific aberrations are ongoing. Combinations of these new therapeutic modalities with current treatment regimens will likely be needed to improve the outcomes of children with relapsed and refractory neuroblastoma.

Original languageEnglish (US)
Article number148
Issue number11
StatePublished - Nov 2018


  • ALK
  • MIBG
  • Neuroblastoma
  • Personalized treatment
  • RET
  • Recurrent neuroblastoma
  • Refractory neuroblastoma
  • Relapsed neuroblastoma
  • Retinoic acid

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health


Dive into the research topics of 'Novel therapies for relapsed and refractory neuroblastoma'. Together they form a unique fingerprint.

Cite this